CA3101210A1 - Methode de traitement avec le tradipitant - Google Patents

Methode de traitement avec le tradipitant Download PDF

Info

Publication number
CA3101210A1
CA3101210A1 CA3101210A CA3101210A CA3101210A1 CA 3101210 A1 CA3101210 A1 CA 3101210A1 CA 3101210 A CA3101210 A CA 3101210A CA 3101210 A CA3101210 A CA 3101210A CA 3101210 A1 CA3101210 A1 CA 3101210A1
Authority
CA
Canada
Prior art keywords
tradipitant
day
opioid
dose
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3101210A
Other languages
English (en)
Inventor
Mihael H. Polymeropoulos
Gunther P. Birznieks
Sharon WALSH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Vanda Pharmaceuticals Inc
Original Assignee
University of Kentucky Research Foundation
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kentucky Research Foundation, Vanda Pharmaceuticals Inc filed Critical University of Kentucky Research Foundation
Publication of CA3101210A1 publication Critical patent/CA3101210A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des méthodes de traitement d'un individu souffrant, ou risquant de souffrir, d'une conséquence indésirable de la consommation d'opioïdes, et de traitement d'un individu qui souffre, ou qui risque de souffrir, d'un manque d'opioïdes, ainsi que l'utilisation de l'antagoniste des récepteurs de la NK-1, le tradipitant, dans le traitement d'un tel individu.
CA3101210A 2018-06-08 2019-06-06 Methode de traitement avec le tradipitant Pending CA3101210A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682831P 2018-06-08 2018-06-08
US62/682,831 2018-06-08
PCT/US2019/035799 WO2019236852A1 (fr) 2018-06-08 2019-06-06 Méthode de traitement avec le tradipitant

Publications (1)

Publication Number Publication Date
CA3101210A1 true CA3101210A1 (fr) 2019-12-12

Family

ID=67003718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3101210A Pending CA3101210A1 (fr) 2018-06-08 2019-06-06 Methode de traitement avec le tradipitant

Country Status (7)

Country Link
US (2) US20210228555A1 (fr)
EP (1) EP3801514A1 (fr)
JP (1) JP7410137B2 (fr)
CN (1) CN112218636B (fr)
BR (1) BR112020024906A2 (fr)
CA (1) CA3101210A1 (fr)
WO (1) WO2019236852A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
WO2005042515A1 (fr) 2003-10-24 2005-05-12 Eli Lilly And Company Formes cristallines de {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
CA3073998A1 (fr) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Traitement ameliore de dermatite atopique au moyen de tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Also Published As

Publication number Publication date
CN112218636A (zh) 2021-01-12
JP2021530557A (ja) 2021-11-11
CN112218636B (zh) 2025-05-06
JP7410137B2 (ja) 2024-01-09
US20240390353A1 (en) 2024-11-28
WO2019236852A1 (fr) 2019-12-12
US20210228555A1 (en) 2021-07-29
BR112020024906A2 (pt) 2021-03-09
EP3801514A1 (fr) 2021-04-14

Similar Documents

Publication Publication Date Title
US20240390353A1 (en) Method of treatment with tradipitant
RU2492858C2 (ru) Композиции и способы профилактики и лечения зависимостей
CN107427502B (zh) 使用川地匹坦的治疗方法
IL266674B1 (en) Preparations, devices and methods for the use of nalamfen and dodecyl maltozide through the nose for the treatment of an opioid overdose.
EP3709984B1 (fr) Combinaison de cannabidiol et de buprénorphine et son utilisation pour le traitement de la douleur chronique
KR20030025902A (ko) 덱스트로메토르판 및 옥시다제 억제제의 환자의 마약 및항진정제의 중단을 위한 용도
AU2015225442A1 (en) Therapeutic uses of ibogaine and related compounds
IL322430A (en) 5-MEO-DMT for use in the treatment of postpartum depression
AU2005223691B2 (en) Methods for treating alcoholism
CN101014325A (zh) 治疗中枢神经系统病症的药物
AU2016302769A1 (en) Antitussive compositions and methods
KR20100022940A (ko) 혈중 화학 물질을 제거하기 위한 방법 및 투약 요법
RU2605283C2 (ru) Фармацевтическая композиция для лечения зависимости у людей
Mucha Preferences for tastes paired with a nicotine antagonist in rats chronically treated with nicotine
CZ355998A3 (cs) Pyridil a pyrimidylpiperaziny pro léčení poruch způsobených odejmutím drogy
CN1226165A (zh) 治疗双相情感障碍的方法
Climko Anticholinergics and Other Medicines
JP2007528891A (ja) 複合鎮痛剤医薬組成物
Li et al. Methadone Usage, Misuse, and Addiction Processes: An Overview
Namratha A Comparison Between Transdermal Fentanyl Patches and Intravenous Fentanyl Infusion for Post Operative Analgesia in Laparoscopic Cholecystectomy Surgeries Done Under GA
AU2011302137A1 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
HK1062402A1 (zh) 使用脫氧駱駝蓬堿治療由精神治療藥物中毒引致的中樞神經系統症狀
HK1062402B (en) Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
HUP0202290A2 (hu) Fájdalomcsillapító hatású kombinációs gyógyászati készítmény
HK1248552B (en) Method of treatment with tradipitant

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240606

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251015

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251211